

JC06 Rec'd PCT/PTO 19 OCT 2005

FILING BY EXPRESS MAIL UNDER C.F.R. §1.10

EXPRESS MAIL NO. EV 731062874 U.S.	DATE OF DEPOSIT: OCTOBER 19, 2005
NAME: <i>Stichelle White</i>	SIGNATURE: <i>Stichelle White</i>
CASE 1-32411A/FMI	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
CHIQUET-EHRISMANN ET AL.
U.S. APPLICATION NO: 10/509,009
35 USC §371 DATE: MAY 3, 2005
FOR: TENASCIN-W COMPOSITIONS AND USES THEREOF

Mail Stop: Assignment Services Division
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Enclosed for filing in the above-referenced patent application, please find the following documents:

1. USPTO Document No. 103011015 (3 pages);
2. Recordation Form Cover Sheet (1 page);
3. Original Executed Assignment (1 page);
4. Return-receipt postcard.

It is believed that no further fees are due with the filing of these documents. If, however, the Commissioner of Patents deems an additional fee is due, authorization is given to charge Deposit Account No. 19-0134 in the name of Novartis.

Respectfully submitted,


John T. Prince
Attorney for Applicants
Reg. No. 43,019

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(617) 871-3346
Date: October 19, 2005



1-32411A/FM/1

JTF

RECEIVED

OCT 12 2005

UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEPTEMBER 28, 2005

PTAS



103011015A

NOVARTIS

CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA, BUILDING 104
EAST HANOVER, NJ 07936-1080UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF NON-RECORDATION OF DOCUMENT

DOCUMENT ID NO.: 103011015

THE ENCLOSED DOCUMENT HAS BEEN EXAMINED AND FOUND NON-RECORDABLE BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. THE REASON(S) FOR NON-RECORDATION ARE STATED BELOW. DOCUMENTS BEING RESUBMITTED FOR RECORDATION MUST BE ACCCOMPANIED BY A NEW COVER SHEET REFLECTING THE CORRECT INFORMATION TO BE RECORDED AND THE DOCUMENT ID NUMBER REFERENCED ABOVE.

THE ORIGINAL DATE OF FILING OF THIS ASSIGNMENT DOCUMENT WILL BE MAINTAINED IF RESUBMITTED WITH THE APPROPRIATE CORRECTION(S) WITHIN 30 DAYS FROM THE DATE OF THIS NOTICE AS OUTLINED UNDER 37 CFR 3.51. THE RESUBMITTED DOCUMENT MUST INCLUDE A STAMP WITH THE OFFICIAL DATE OF RECEIPT UNDER 37 CFR 3. APPLICANTS MAY USE THE CERTIFIED PROCEDURES UNDER 37 CFR 1.8 OR 1.10 FOR RESUBMISSION OF THE RETURNED PAPERS, IF THEY DESIRE TO HAVE THE BENEFIT OF THE DATE OF DEPOSIT IN THE UNITED STATES POSTAL SERVICE.

SEND DOCUMENTS TO: U.S. PATENT AND TRADEMARK OFFICE,
MAIL STOP: ASSIGNMENT SERVICES DIVISION, P.O. BOX 1450, ALEXANDRIA, VA 22313.
IF YOU HAVE ANY QUESTIONS REGARDING THIS NOTICE,
YOU MAY CONTACT THE INDIVIDUAL WHOSE NAME APPEARS ON THIS NOTICE AT
571-272-3350.

1. THE DOCUMENT SUBMITTED FOR RECORDING IS NOT ACCEPTABLE. THE EXECUTION DATE OF THE ASSIGNMENT DOCUMENT IS AFTER THE PATENT AND TRADEMARK OFFICE MAIL ROOM DATE.

PAULA MCCRAY, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

DOCKETED FOR: Oct. 28, 2005



103011015

To the Honorable Commissioner of Pa

1. Name of conveying party(ies):

Ruth Chiquet-Ehrismann and
Arnaud Scherberich

2. Name and address of receiving party(ies)

Name: **Novartis International AG**Additional name(s) of conveying party(ies) attached? Yes No

3. Nature of conveyance:

Assignment Merger
 Security Agreement Change of Name
 Other _____

Street Address: _____

City: Basel + State: Switzerland ZIP: 4002Execution Date: **Aug. 19, 2005 and Aug. 20, 2005**Additional name(s) & address(es) attached? Yes No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

10/509,009 and PCT/EP03/003150

B. Patent No.(s)

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Novartis6. Total number of applications and patents involved: 1Internal Address: Corporate Intellectual Property7. Total fee (37 CFR 3.41) \$ 40.00Street Address: One Health Plaza, Building 104 EnclosedCity: East Hanover State: NJ ZIP: 07936-1080 Authorized to be charged to deposit account and any other additional fees required.

05/09/2005 LLANDGRA 00000055 190134 10509009

8. Deposit account number:

19-0134 (in the name of Novartis)

(Attach duplicate copy of this page if paying by deposit account)

02 FC:8021

40.00 DA

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

John T. PrinceName of Person Signing
Reg. No. 43,019

Signature

May 3, 2005

Date

 Certificate of Express Mail belowTotal number of pages including cover sheet, attachments, and document: 3

Mail documents to be recorded with required cover sheet information to:

Director of the US Patent and Trademark Office, PO Box 1450

Alexandria, VA 22313-1450

FILING BY EXPRESS MAIL UNDER 37 CFR 1.10

Express Mail No.: **EV 524615121 US**Date of Deposit: **May 3, 2005**Name: **Sandra A. Nelson**

Signature:

ASSIGNMENT

I / We **Ruth CHIQUET-EHRISMANN, Gstadstrasse 45, 4153 Reinach, Switzerland, citizen of Switzerland and**
Arnaud SCHERBERICH, 1, rue des Ecrins, 68400 Riedisheim, France, citizen of France,

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to **Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, an organization registered according to the laws of Switzerland, of Maulbeerstrasse 66, 4058 Basel, Switzerland**, its successors, assigns and legal representatives all my/our right, title and interest, in and for the United States of America, in and to the invention entitled:

Tenascin-W compositions and uses thereof

invented by me/us and described in the international application

No. PCT/EP 2003/003150 filed March 26, 2003


and all United States Letters Patent which may be granted therefor, and all divisions, reissues, continuations and extensions thereof, the said interest being the entire ownership of the said Letters Patent when granted, to be held and enjoyed by the said **Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research**, its successors, assigns or other legal representatives, to the full end of the term for which said Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this assignment and sale had not been made;

And I/we hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to the said **Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research**.

Signed on



Ruth CHIQUET-EHRISMANN



Arnaud SCHERBERICH

